METHOD FOR CORRECTION OF PULMONARY HYPOPLASIA IN FETUS CONGENITAL DIAPHRAGMATIC HERNIA IN RATS USING SELECTIVE INHIBITOR OF SPECIFIC PDE-5 CGMP Russian patent published in 2023 - IPC A61K31/497 A61P11/00 G09B23/28 

FIELD: medicine; obstetrics; gynecology; pulmonology.

SUBSTANCE: invention relates to medicine, to the field of obstetrics and gynecology, pulmonology, and specifically to a method for pulmonary hypoplasia correction in fetus congenital diaphragmatic hernia in rats. The method includes lung hypoplasia simulation by oral administration of 100 mg of nitrofen on the 9th day of pregnancy and use of inhibitor of specific phosphodiesterase 5 cyclic guanosine monophosphate - PDE-5 cGMP for its correction. Use tadalafil as an inhibitor of specific PDE-5 cGMP, which is administered subcutaneously, starting from the 9th day of pregnancy at a dosage of 3.3 mg every day until the 20th day of pregnancy.

EFFECT: invention provides improvement of vascularization of interalveolar septa and increase in the number of alveoli after the use of tadalafil in a nitrafen-induced VDH model in rats.

1 cl, 3 tbl